CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 592 enrolled
Drug / intervention
Alteplasedrug
Likely dose
Alteplase 0.9 mg/kgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT06058884
NCT06058884Phase 4Completed
CompareCT.gov

Predictors of the Unfavourable Outcomes in Acute Ischemic Stroke Patients Treated With Alteplase, a Multi-centre Prospective Study

Kafrelsheikh University·interventional·Posted Sep 28, 2023·Updated Oct 10, 2023

In Brief

A Phase 4 clinical trial evaluating Alteplase for Ischemic Stroke and Alteplase Adverse Reaction. Completed, enrolled 592 participants across 1 site.

Detailed Summary

The investigators evaluated whether the characteristics of ischemic stroke patients, door-to-needle time, and stroke risk factors were predictive variables for unfavourable outcomes.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsIschemic Stroke, Alteplase Adverse Reaction
CountriesEgypt
Collaborators--

Timeline

Phase 4CompletedFinished
20222023202420252026
First PostedSep 28, 2023
Enrollment StartJan 3, 2022
Primary CompletionJun 3, 2023
Study CompletionJun 29, 2023
TodayJul 1, 2026
Enrollment to primary: 1.4 yearsPosted 2.8 years ago

Interventions

Alteplasedrug

Following the guidelines set forth by the American Heart Association/American Stroke Association (AHA/ASA), inclusion and exclusion criteria for alteplase were established; 0.9 mg/kg of alteplase up to a maximum dose of 90 mg was administered intravenously to eligible individuals within 4.5 hours of the beginning of their clinical manifestations (10% bolus, 90% infusion in 1 hour). After receiving IV-alteplase, all patients continued their management and rehabilitation in the stroke unit.